The tumor microenvironment (TME) plays a pivotal role in cancer progression, yet its establishment and functionality remain poorly understood due to its intricate cellular composition. A study utilizing a mouse genetic system, mosaic analysis with double markers (MADMs), revealed insights into TME evolution in sonic hedgehog (SHH)-activated medulloblastomas, highlighting the importance of astrocytic trans-differentiation in sustaining tumor growth through a multicellular paracrine feedback loop (ref: Yao doi.org/10.1016/j.cell.2019.12.024/). In the context of atypical teratoid/rhabdoid tumors (ATRTs), an international consensus was reached on the molecular subgrouping of these tumors, identifying three distinct subgroups that exhibit genetic, epigenetic, and clinical heterogeneity, emphasizing the need for standardized nomenclature and classification in future studies (ref: Ho doi.org/10.1093/neuonc/). Furthermore, Erdheim-Chester disease (ECD), characterized by MAPK pathway alterations, demonstrated varied responses to conventional versus targeted therapies, with targeted treatments yielding significantly higher rates of complete metabolic responses (ref: Bhatia doi.org/10.1093/neuonc/). The integration of machine learning workflows for DNA methylation data has emerged as a promising approach for precision cancer diagnostics, enhancing molecular tumor classification through unbiased class probability estimation (ref: Maros doi.org/10.1038/s41596-019-0251-6/). Lastly, the modulation of microglial function by VGF-derived peptides was shown to reduce neuropathology in Alzheimer's disease models, indicating potential therapeutic avenues for neurodegenerative conditions (ref: El Gaamouch doi.org/10.1186/s13024-020-0357-x/).